[Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program].

UNLABELLED: The article presents preliminary results of a subanalysis of PREVOSHODSTVO (SUPERIORITY) phase IV study. Aim of this subanalysis was to assess efficacy and tolerability of a fixed-dose perindopril/amlodipine combination (FDPAC) in patients with arterial hypertension (AP) uncontrolled on previous treatment with angiotensin receptor blockers (ARBs).

MATERIAL AND METHODS: We included in this analysis 125 patients (70.4% women, mean age 57.2+/-10.0 years), final analysis of efficacy was performed on 124 patients. Before inclusion in the study 47 patients received ARB either as monotherapy (n=47), or components of free-dose (n=49) and fixed-dose (n=28) dual combinations with other antihypertensive drugs. Dose. of FDPAC was determined by physician. Duration of observation period was 24 weeks.

RESULTS: After 2weeks significant reduction of blood pressure (BP) (from 159.9+/-8.8/93.8+/-6.8 to 143.9+/-10.7/86.4+/-6.5 mm Hg, p<0.001) was noted. At final visit mean BP was 125.1+/-7.1/78.1+/-4.7 mm Hg. Number of patients with target BP (< 140/90 mm Hg) was 24, 75 and 97% after 1, 3, and 6 months, respectively. Visit-to-visit systolic BP variability by the end of the observation period decreased to 3.8+/-2.3 mm Hg.

CONCLUSION: In patients, whose hypertension was not controlled by treatment with ARBs the fixed-dose combination of perindopril/amlodipine provided high percentage of achievement of target BP and reduction of long-term BP variability.